• 1
    Petrylak DP, Tangen CM, Hussain MHA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 151320
  • 2
    Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 150212
  • 3
    Berthold DR, Pond GR, Roessner M et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008; 14: 27637
  • 4
    Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 2425
  • 5
    Mountzios I, Bournakis E, Efstathiou E et al. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology 2011; 77: 6827
  • 6
    Di Lorenzo G, Buonerba C, Faiella A et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 2011; 107: 2349
  • 7
    Eymard J-C, Oudard S, Gravis G et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010; 106: 9748
  • 8
    Loriot Y, Massard C, Gross-Goupil M et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010; 46: 17702
  • 9
    Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2003; 89: 96870
  • 10
    Schallier D, Decoster L, Braeckman J, Fontaine C, Degrève J. Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC): an Observational Study in a Single Institution. Anticancer Res 2012; 32: 63341
  • 11
    Caffo O, Pappagallo G, Brugnara S et al. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology 2012; 79: 6449
  • 12
    Oudard S, Kramer G, Creppy L et al. Management of metastatic castration-resistant prostate cancer (mCRPC) After an initial good response to first-line docetaxel (D) – a retrospective study on 270 patients (pts). Eur J Cancer 2011; 47 (Suppl. 1): S499S500. 7049 [abstract]
  • 13
    Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 1: 114859
  • 14
    de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 26: 19952005
  • 15
    de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 114754
  • 16
    Lin AM, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol 2007; 61: 24354